Compare iShares Russell 2000 ETF (IWM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Russell 2000 ETF trades at $271.97 (market cap $77.75B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Russell 2000 ETF is far larger — about 10.3× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Russell 2000 ETF is more actively traded (27,728,271 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IWM | SYRE | |
|---|---|---|
Market Cap | $77.75B | $7.52B |
Volume | 27,728,271 | 1,441,031 |
52-Week High | $305.06 | $108.92 |
52-Week Low | $229.13 | $22.18 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% with bearish technical signals from moving averages. The ETF faces headwinds as small-caps underperform large-caps, with recent Fed rate hikes pressuring the sector. Technical indicators show oversold conditions with RSI at 38.61, while support sits at $276. Recent news highlights IWM's decade-long underperformance versus the S&P 500, raising questions about the small-cap premium.
The outlook remains cautious given macroeconomic pressures and sector rotation away from small-caps. Higher interest rates typically disadvantage small companies with greater borrowing needs, while broader market concentration in tech giants reduces small-cap participation. However, current valuations may offer long-term value if economic conditions stabilize.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
